Read our Recent Headlines


Sep 28, 2016 by Dave Sobek

September 28 Biotech Update

The sector continues to do well but there seems to be a bifurcation occurring where the SMID are outperforming the large caps. Usually when investors come back into a sector.

Share 0 Comments Read more
Sep 27, 2016 by Dave Sobek

September 27 Biotech Update

We got some interesting biotech news and I thought there would be only one to talk about but we have three I want to touch on so I will save.

Sep 26, 2016 by Dave Sobek

September 26 Biotech Update

Nothing really to move the sector to start the week, so it looks like we sell off with the rest of the market. This price action does not change my.

Sep 23, 2016 by Dave Sobek

September 23 Biotech Update

The sector seems to be quieting down a little and perhaps a little bit of consolidation of the recent move is in the cards. All in all, however, it seems.

Sep 21, 2016 by Dave Sobek

September 21 Biotech Update

The sector is certainly heating up and we still seem to be at the point where good news is rewarded and bad news is creating isolated damage. Not only do.

Sep 20, 2016 by Jason DeLorenzo

Dave-Trading – September Edition – 3 shots

*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.

Sep 20, 2016 by Dave Sobek

September 20 Biotech Update

A little but more news today and there are actually some interesting implications. Yesterday was actually not great in terms of trading given the weakening towards the end of the.

More From All Reports

Introduction


Quick Facts

10

Analysts

500

Clients

22k

Followers

900

Reports

2.7k

Comments

5

Years

Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!


      Join      

 Learn More